Company: TXG
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050332
Chunk: 52

Company: 10x Genomics, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 8
Chunk 52
---
.0%Expected dividend yield—%In March 2024, the Company granted 219,168 PSUs under the 2019 Plan to certain members of management, which are subject to the achievement of certain market-condition and performance-condition goals established by the Company’s Compensation Committee of the Board of Directors.As of September 30, 2025, the measurement periods for the 2025 and 2024 PSUs were not completed and the market and performance criteria for the stock awards was not met and therefore no shares vested or became exercisable.2019 Employee Stock Purchase PlanA total of 4,909,589 shares of Class A common stock were reserved for issuance under the 2019 Employee Stock Purchase Plan (“ESPP”). The price at which Class A common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower.During the nine months ended September 30, 2025 and 2024, 446,766 and 192,869 shares of Class A common stock, respectively, were issued under the ESPP. There were no shares of Class A common stock issued under the ESPP during the three months ended September 30, 2025 and 2024. As of September 30, 2025, there were 3,481,248 shares available for issuance under the ESPP.

18

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

9.    Net Loss Per Share

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Stock options to purchase common stock3,700,635 5,284,430 3,700,635 5,284,430 Restricted stock units8,466,033 6,404,105 8,466,033 6,404,105 Shares committed under ESPP320,514 176,160 320,514 176,160 Total12,487,182 11,864,695 12,487,182 11,864,695 

19

Table of Contents

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations